DaVita
DVA · What the business does, what can go wrong, and how options sellers approach it
What it does
DaVita runs outpatient dialysis centers. Dialysis does the work of the kidneys for people with kidney failure, filtering waste and extra fluid from the blood.
The company operates mainly in the United States, with clinics in several other countries. It also offers home dialysis programs and support for patients with earlier-stage kidney disease.
How it makes money
DaVita is paid for each treatment it provides. The payers are mostly government programs, especially Medicare, and commercial health insurers.
Government rates are set by regulators, so they tend to be tight. Commercial insurers usually pay more per treatment. A small share of patients on commercial plans can therefore account for a large share of profit. Payer mix is a major driver of the economics.
Why investors own it
- Steady demand: Kidney failure is a chronic condition, and patients generally need regular treatment to stay alive.
- Scale: With a large network of clinics, DaVita can spread costs for purchasing, staffing and administration.
- Cash generation: The business has historically produced substantial cash, often used for share repurchases.
What can go wrong
- Reimbursement changes: Medicare rate decisions or policy shifts can pressure margins.
- Payer mix: If commercial patients move to government plans, or insurers negotiate lower rates, profit can fall quickly.
- Labor costs: Staffing shortages or wage inflation hurt results.
- Patient volumes: Newer medicines and changing treatment patterns could affect how many patients need dialysis.
- Concentration: Heavy reliance on a small number of large payers, plus legal and regulatory scrutiny, adds risk.
What to watch
- Treatments per day (volume growth)
- Revenue per treatment
- Commercial versus government payer mix
- Medicare payment rule updates
- Labor and clinic operating costs
- Patient mortality and census trends
- Free cash flow and share repurchase activity
Options income angle
Options on DVA are listed across several expirations, but they trade less than options on the largest US stocks. Wider bid-ask spreads, especially on strikes far from the current price, can make execution costs more noticeable.
Implied volatility tends to rise around quarterly earnings and news on Medicare payment rules or insurer contracts. Option prices around those events tend to be higher because the market expects a larger move.
One caution: a reimbursement or payer-mix surprise can gap the stock past a strike. A covered call can cap the upside, and a cash-secured put can leave you owning shares after a large drop.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 11, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
DaVita's 2025 revenue rose, but operating income fell as U.S. dialysis treatment volume declined and costs per treatment climbed, while international operations grew quickly. The filing stresses that commercially insured patients generate nearly all of the company's profit. It also flags an April 2025 cybersecurity incident, a heavy debt load, and large share buybacks.
How the business did
- Total consolidated revenues were $13,643 million, up 6.5% from $12,816 million. Operating income was $2,044 million, down 2.2% from $2,090 million. Adjusted operating income, which strips out items management calls unusual such as cyber charges and a legal accrual, was $2,094 million, up 5.7%.
- U.S. dialysis revenue rose 3.5% to $11,793 million. Average revenue per treatment was $409.56 against $391.32, helped by phosphate binders (oral drugs that reduce phosphate absorption) moving into the Medicare payment bundle and by annual rate increases. Treatments fell to 28,733,980 from 29,046,346, which management attributes to higher mortality and a more severe flu season. Patient care costs per treatment rose 5.9%.
- Other ancillary services revenue rose 27.3% to $1,922 million, led by international revenue of $1,346 million, up 37.8%. The U.S. integrated kidney care business posted operating income of $22 million after a loss of $(18) million. International operating income fell to $89 million from $127 million, partly because of a $25 million legal charge.
- Operating cash flows were $1,887 million and free cash flows were $1,024 million. The company repurchased 12,678,623 shares for $1,788 million, a 14.9% net reduction in shares outstanding. Debt expense rose to $580 million from $470 million.
Risks specific to this company
- Commercial insurance dependence: Commercial payors represent approximately 32% of U.S. dialysis patient service revenues but generate nearly all profit. The filing points to expired enhanced ACA premium tax credits, restrictions on charitable premium assistance, and the Supreme Court's Marietta decision as threats to the number of commercially insured patients. Several large payor contracts are being renegotiated at the same time.
- Government program exposure: Approximately 68% of U.S. dialysis patient service revenues come from government-based programs. The One Big Beautiful Bill Act (OBBBA) phases down federal Medicaid spending, and the Department of Veterans Affairs can end its contract without cause on short notice.
- Cybersecurity incident: An April 2025 attack took certain data, including personal and health information, and disrupted operations. It hurt billing and collections and new patient intake, and the company says it continues to incur expenses and lose revenue from it.
- Debt: The company has a senior secured credit agreement with an up to $1.5 billion revolving line of credit and term loans, plus $6.25 billion aggregate principal amount of senior notes. Some debt carries variable interest rates, covenants apply, and substantially all assets secure the credit facilities.
- Supplier concentration: A substantial portion of vendor spend sits with a limited number of suppliers. A September 2024 storm that damaged a supplier's plant raised costs and slowed home dialysis growth into early 2025.
- Legal scrutiny: The company has received subpoenas and civil investigative demands from the federal government about historical billing practices. Qui tam suits (brought by private whistleblowers on the government's behalf) and audits are also possible, with penalties up to exclusion from Medicare and Medicaid.
What management is watching
- 2026 volumes and income: Management expects approximately flat U.S. treatment volumes and operating income growth. Higher revenue per treatment from rate increases and better collections should drive it, partly offset by the expired premium tax credits and higher labor and other costs.
- Medicare rates and phosphate binders: CMS finalized an average reimbursement increase of 2.2% for 2026. The temporary add-on payment for phosphate binders is set to expire at the end of 2026, and management expects their impact on operating income to be approximately flat.
- Growth and spending: Management expects operating income growth in international and integrated kidney care, and expects 2026 capital expenditures to rise. It also expects lower debt expense and positive other income as losses from its Mozarc investment decline.
- Capital return: After year-end, the company repurchased 1,772,872 shares for $217 million through February 6, 2026.
- Measures cited: Management points to treatment volume, revenue per treatment, patient care costs, adjusted operating income, free cash flow, and a leverage ratio target of 3.0x to 3.5x.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
DaVita's third quarter showed steady U.S. dialysis results but weaker overall profit. Operating income fell to $499 million from $579 million in the second quarter, mainly because of a $62 million goodwill and other asset impairment charge on its China business. Management also flagged a rollout of expanded hemodialysis, a newer therapy that clears more toxins from the blood, along with commercial insurance mix pressure.
How the business did
- Quarter versus the prior quarter: The filing compares the third quarter with the second quarter. Total consolidated revenues were $3,578 million, up from $3,554 million. Adjusted operating income, which strips out the China impairment, was $561 million versus $579 million.
- U.S. dialysis: Revenues were $3,050 million and operating income was $544 million. Revenue per treatment was $415.25 versus $415.87, while patient care costs per treatment rose to $280.22 from $277.40, mostly on medical supplies expense.
- Other segments: Operating income at the kidney care arm (IKC) dropped to $4 million from $40 million on lower shared savings. International had an operating loss of $16 million after the impairment.
- Nine months versus last year: Revenues were $10,548 million versus $10,023 million. Operating income was $1,560 million versus $1,483 million. U.S. dialysis revenue per treatment rose to $416.22 from $405.15.
- Cash and capital return: Operating cash flow was $1,330 million versus $1,346 million. Free cash flow was $672 million versus $716 million. Share repurchases were $870 million (5.8 million shares) versus $1,464 million (10.0 million shares) a year earlier.
What management is watching
- Expanded hemodialysis: The company expects to offer it to the vast majority of eligible patients in November. It has dedicated resources to securing supply and training clinical staff, and expects costs from supplier transitions.
- Commercial mix and policy: The expiry of enhanced premium tax credits at the end of 2025 has hurt Affordable Care Act exchange enrollment and the share of patients on commercial insurance, which pays more than government programs. On October 28, 2026, CMS issued a final rule for 2027 that it estimates will increase average reimbursement by 2.7%. HHS also released a 2026 Kidney Care National Plan on October 20, 2026, which the company says it will monitor.
- Costs: Labor costs are still rising and union petitions have been filed at a number of California clinics. Management expects productivity gains to continue throughout the year and technology spending to grow more slowly.
- Measures cited: Management points to adjusted operating income and free cash flow, both non-GAAP (not based on standard accounting rules). As of September 30, 2026, $1.42 billion was available on the $1.5 billion revolving credit line, with $80 million drawn.
Follow DVA in Kortex
The Kortex app shows DVA's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.